Loading... Please wait... Loading... Please wait...
ESTIMATED
11/10/2021
11/10/2021
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | $1.58 | $1.58 | $1.58 |
| Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
Navidea Biopharmaceuticals, Inc. last posted its earnings results on Wednesday, November 10th, 2021. The company reported $-0.08 earnings per share for the quarter, topping analysts' consensus estimates of $-0.11 by $0.03. The company had revenue of 0 for the quarter and had revenue of 65,652 for the year. Navidea Biopharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-0.59 diluted earnings per share) and currently has a price-to-earnings ratio of 0.02. Navidea Biopharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 27th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 11/14/2023 | Q3 2023 | -$0.02 | $0 | $0 | 08/11/2023 | Q2 2023 | $0.12 | $0 | 05/11/2023 | Q1 2023 | -$0.02 | $0 | 03/27/2023 | Q4 2022 | -$0.17 | $610 | 11/14/2022 | Q3 2022 | -$0.21 | $7,516 | 08/15/2022 | Q2 2022 | -$0.10 | $6,519 | 05/16/2022 | Q1 2022 | -$0.10 | $0 | 03/28/2022 | Q4 2021 | -$0.12 | $50,348 | 11/12/2021 | Q3 2021 | -$0.08 | $311,218 | $96,382 | 08/12/2021 | Q2 2021 | -$0.09 | $600,000 | $261,046 | 05/13/2021 | Q1 2021 | -$0.11 | $123,737 | 03/26/2021 | Q4 2020 | -$0.11 | $219,251 | 11/13/2020 | Q3 2020 | -$0.11 | $246,022 | $6,773 | 08/14/2020 | Q2 2020 | -$0.10 | $295,746 | $8,920 | 05/15/2020 | Q1 2020 | -$0.13 | $15,221 | 03/18/2020 | Q4 2019 | -$0.15 | $2,680 | 11/08/2019 | Q3 2019 | -$0.17 | $236,811 | $4,895 | 08/09/2019 | Q2 2019 | -$0.24 | $162,557 | $15,893 | 05/09/2019 | Q1 2019 | -$0.24 | $97,558 | 03/15/2019 | Q4 2018 | -$0.33 | $35,040 |
|---|
A. Navidea Biopharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 27th, 2024 based off last year's report dates.
A. In the previous quarter, Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) reported $-0.08 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.11 by $0.03.
A. The conference call for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be read online.
A. Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) has a recorded annual revenue of $65,652.
A. Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) has a recorded net income of $65,652. Navidea Biopharmaceuticals, Inc. has generated $-0.59 earnings per share over the last four quarters.
A. Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) has a price-to-earnings ratio of 0.02 and price/earnings-to-growth ratio is -0.
